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Scope and purpose of the guideline 
Need for a revised management guideline 
The British Society for Rheumatology/British Health Professionals in Rheumatology 
guideline for the management of gout was published in 20071. A revised and 
updated guideline is now required because of the availability of new pharmaceutical 
treatment options; recent increases in the incidence, prevalence and severity of 
gout2; continuing suboptimal management in both primary and secondary care2,3; 
and better understanding of patient and provider barriers to effective care.4,5 
 
Objectives of the guideline 
To offer revised and updated, concise, patient-focussed, evidence-based, expert 
recommendations for the management of gout in the UK.  
 
Target Audience 
To provide assistance to doctors and allied health professionals who treat and 
manage patients with gout in primary care and hospital practice.  
 
Areas that the guideline does not cover 
This guideline does not cover the diagnosis and investigation of gout. 
 
This guideline has been reviewed and endorsed by the Royal College of General 
Practitioners (RCGP). 
 
Key recommendations from this guideline 
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Management of Acute Attacks 
I. Educate patients to understand that attacks should be treated as soon as 
an attack occurs and ensure that patients are aware of the importance of 
continuing any established urate-lowering therapy during an 
attack.(Level of Evidence (LoE)  IV, Strength of Recommendation (SOR) 
90%) 
 
II. Affected joints should be rested, elevated and exposed in a cool 
environment. Bed-cages and ice-packs can be effective adjuncts to 
management. (LoE Ib (ice-packs), IV (other), SOR 89%) 
 
III. A non-steroidal anti-inflammatory drug (NSAID) at maximum dose or 
colchicine in doses of 500 micrograms bd-qds are the drugs of choice 
when there are no contraindications. Choice of first line agent will 
depend on patient preference, renal function and co-morbidities. 
Patients on NSAIDs or coxibs should be co-prescribed a gastro-protective 
agent. (LoE Ia, SOR 95%) 
 
IV. Joint aspiration and injection of a corticosteroid are highly effective in 
acute monoarticular gout and may be the treatment of choice in patients 
with acute illness and co-morbidity. A short course of oral corticosteroid 
or a single injection of an intra-muscular corticosteroid are alternatives in 
patients who are unable to tolerate NSAIDs/colchicine and in whom 
intra-articular injection is not feasible. Such systemic therapy is also 
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appropriate for oligo- or polyarticular attacks of gout. (LoE Ib (oral), III 
(intra-articular, intra-muscular), IV (oligo/polyarticular attacks), SOR 94%) 
 
V. In patients with acute gout where response to monotherapy is 
insufficient,    combinations of treatment can be used. (LoE IV, SOR 80%) 
 
VI. Interleukin-1 inhibitors may be considered in patients who have 
previously not responded adequately to standard treatment of acute 
gout (although not approved by NICE). (LoE Ib (canakinumab, rilonacept), 
III (anakinra), SOR 61%) 
 
 
Modification of lifestyle and risk factors 
 
VII. If diuretic drugs are being used to treat hypertension rather than heart 
failure, an alternative antihypertensive agent can be considered as long 
as blood pressure is controlled. (LoE IV, SOR 91%) 
VIII. All patients with gout should be given verbal and written information 
about: the causes and consequences of gout and hyperuricaemia; how to 
manage acute attacks; lifestyle advice about diet, alcohol consumption 
and obesity; and the rationale, aims and use of urate-lowering therapy to 
target urate levels. Management should be individualised and take into 
account co-morbidities and concurrent medications. Illness perceptions 
and potential barriers to care should be discussed. (LoE IIb, SOR 96%) 
IX. In overweight patients, dietary modification to achieve a gradual 
reduction in body weight and subsequent maintenance should be 
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encouraged. Diet and exercise should be discussed with all patients with 
gout, and a well-balanced diet low in fat and added sugars, and high in 
vegetables and fibre should be encouraged: sugar sweetened soft drinks 
containing fructose should be avoided; excessive intake of alcoholic 
drinks and high purine foods should be avoided; and inclusion of 
skimmed milk and/or low fat yoghurt, soy beans and vegetable sources 
of protein and cherries, in the diet should be encouraged. (LoE  I (vitamin 
C and skimmed milk), III (others), SOR 92%) 
X. Patients with gout and a history of urolithiasis should be encouraged to 
drink >2litres of water daily and avoid dehydration. Alkalinisation of the 
urine with potassium citrate (60mEq/day) should be considered in 
recurrent stone formers (LoE IV, SOR 57%) 
XI. Cardiovascular risk factors and co-morbid conditions such as cigarette 
smoking, hypertension, diabetes mellitus, dyslipidaemia, obesity and 
renal disease should be screened for in all patients with gout, reviewed 
at least annually and managed appropriately. (LoE III, SOR 90%) 
 
Optimal use of urate-lowering therapies 
XII. The option of urate-lowering therapy (ULT) should be explained to 
patients when the diagnosis is confirmed and they are being given 
information about gout. Patients should be fully involved in the decision 
as to when to commence ULT. The importance of taking ULT regularly 
and continually to prevent the return of gout attacks should be explained. 
Patients should be supported during the process of lowering their serum 
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uric acid levels as it can cause an increase in gout flares during this time. 
(LoE Ib, SOR 94%) 
XIII. ULT should be discussed and offered to all patients who have a diagnosis 
of gout. ULT should particularly be advised in patients with: recurring 
attacks  (≥2 attacks in 12 months); tophi; chronic gouty arthritis; joint 
damage; renal impairment (eGFR<60ml/min); a history of urolithiasis; 
diuretic therapy use; and primary gout starting at a young age.  (LoE Ia 
(attacks, tophi, chronic gouty arthritis, joint damage, renal impairment), 
III (urolithiasis), IV (diuretics, young age), SOR 95%) 
XIV. Commencement of ULT is best delayed until inflammation has settled as 
ULT is better discussed when the patient is not in pain. (LoE IV, SOR 94%) 
XV. The initial aim of ULT is to reduce and maintain the serum uric acid (sUA) 
level at or below a target level of 300 µmol/L to prevent further urate 
crystal formation and to dissolve away existing crystals. The lower the 
sUA the greater the velocity of crystal elimination. After some years of 
successful treatment, when tophi have resolved and the patient remains 
free of symptoms, the dose of ULT can be adjusted to maintain the sUA 
at or below a less stringent target of 360μmol/l to avoid further crystal 
deposition and the possibility of adverse effects that may be associated 
with a very low sUA. (LoE III (sUA target<300 µmol/L), -IV (subsequent 
dose adjustment to sUA<360µmol/L), SOR 97%) 
XVI. Allopurinol is the recommended first-line ULT to consider. It should be 
started at a low dose (50-100mg daily) and the dose then increased in 
100mg increments approximately every 4 weeks until the sUA target has 
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been achieved (maximum dose 900mg). In patients with renal 
impairment smaller increments (50mg) should be used and the 
maximum dose will be lower, but target urate levels should be the same. 
(LoE Ib (dose escalation), III (dose adjustment for renal function), SOR 
97%) 
XVII. Febuxostat can be used as an alternative second line xanthine oxidase 
(XO) inhibitor for patients in whom allopurinol is not tolerated or whose 
renal impairment prevents allopurinol dose escalation sufficient to 
achieve the therapeutic target. Start with a dose of 80mg daily and, if 
necessary, increase after 4 weeks to 120mg daily, to achieve therapeutic 
target. (LoE Ia, SOR 90%) 
XVIII. Uricosuric agents can be used in patients who are resistant to, or 
intolerant of, XO-inhibitors. The preferred drugs are sulfinpyrazone (200-
800 mg/day) or probenecid (500-2000mg/day) in patients with normal or 
mildly impaired renal function, or benzbromarone (50-200mg/day) in 
patients with mild-moderate renal insufficiency. (LoE Ia, SOR 92%) 
XIX. Losartan and fenofibrate should not be used as a primary ULT but where 
treatment for hypertension or dyslipidaemia, respectively, are required, 
they may be considered as they have a weak uricosuric effect. Vitamin C 
supplements (500mg – 1500mg daily) also have a weak uricosuric effect. 
(LoE III, SOR 89%) 
XX. A uricosuric agent can be used in combination with a xanthine oxidase 
inhibitor in patients who do not achieve a therapeutic serum urate target 
with optimal doses of monotherapy. (LoE III, SOR 88%) 
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XXI. Colchicine 500micrograms bd or od should be considered as prophylaxis 
against acute attacks resulting from initiation or up-titration of any ULT 
and continued for up to 6 months. In patients who cannot tolerate 
colchicine, a low-dose NSAID or Coxib, with gastroprotection, can be 
used as an alternative providing there are no contraindications. (LoE Ib, 
SOR 86%) 
 
The full guideline, available at Rheumatology online, contains specific 
recommendations for management of gout in special groups: patients with renal 
sufficiency, severe refractory tophaceous gout, and in pregnancy. Figure 1 illustrates 
the suggested care pathway. 
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Figure 1 Algorithm for the management of gout 
 
 
 
 
 
 
  
